Search

CN-121985954-A - Methods and compositions for reducing muscle loss associated with weight loss and/or inhibiting sarcopenia

CN121985954ACN 121985954 ACN121985954 ACN 121985954ACN-121985954-A

Abstract

Methods and compositions for reducing and/or inhibiting sarcopenia associated with weight loss in a mammal by administering a composition comprising an egg yolk derived product are disclosed. In one non-limiting embodiment, the sarcopenia and/or sarcopenia is caused by weight-loss drugs such as semaglutin or telipopeptide.

Inventors

  • Joseph Manelo

Assignees

  • 迈欧斯公司

Dates

Publication Date
20260505
Application Date
20240912
Priority Date
20230912

Claims (10)

  1. 1. A method for reducing muscle loss and/or inhibiting sarcopenia due to weight loss in a mammal, the method comprising administering to the mammal a composition comprising an egg yolk derived product.
  2. 2. The method of claim 1, wherein the sarcopenia and/or sarcopenia is caused by administration of a weight-loss drug and/or a low calorie diet.
  3. 3. The method of claim 2, wherein the weight-reducing drug comprises semaglutin or telipopeptide.
  4. 4. The method of claim 1, wherein the composition comprising the egg yolk derived product is administered once daily.
  5. 5. The method of claim 1, wherein the composition comprising the egg yolk derived product is administered twice daily.
  6. 6. The method of claim 1, wherein the composition comprising the egg yolk derived product is administered three times per day.
  7. 7. The method of claim 1, wherein the composition comprising egg yolk derived product comprises about 33% protein.
  8. 8. The method of claim 1, wherein the composition comprising egg yolk derived product comprises about 2 grams of protein per dose.
  9. 9. The method of claim 1, wherein the composition comprises a fertilized egg yolk derived product.
  10. 10. The method of claim 1, wherein the fertilized egg yolk derived product is FORTETROPIN.

Description

Methods and compositions for reducing muscle loss associated with weight loss and/or inhibiting sarcopenia This patent application claims priority from U.S. provisional application serial No. 63/582,071, filed on 9/12 of 2023, the teachings of which are incorporated herein by reference in their entirety. Technical Field Disclosed herein are methods and compositions for reducing muscle loss and/or inhibiting muscle loss associated with weight loss in humans by administering a composition comprising an egg yolk derived product. In one non-limiting embodiment, the sarcopenia and/or sarcopenia is caused by a weight-loss drug (e.g., without limitation, semaglutin or telipopeptide). Background Semaglutin is a common name for Ozempic and Wegovy, belonging to a class of drugs known as incretin analogues. These drugs ensure that the pancreas releases sufficient insulin when blood glucose levels are high. In addition, semaglutin acts as a long-acting and potent glucagon-like peptide-1 receptor agonist, thereby inducing satiety and delaying gastric emptying in humans, enabling reduced calorie intake. While the use of semaglutin under the advice of a physician is safe, this and other weight-loss drugs such as telopoptin may lead to rapid weight loss, which may also lead to decreased muscle mass, decreased bone density and decreased resting metabolic rate, resulting in sarcopenia, i.e. gradual loss of muscle mass, strength and function. Sarcopenia most commonly affects the elderly and is often associated with aging. However, without proper diet and exercise, the use of GLP-1 based drugs such as Ozempic or Wegovy rapidly reduces body weight, and may also cause sarcopenia (sometimes referred to as "lean body mass") at any age, thereby reducing a person's endurance and ability to perform daily activities (e.g., easily climb stairs), negatively impacting the person's quality of life. To alleviate these side effects, doctors recommend increasing protein intake by taking a protein-rich diet, typically 25-30 grams of protein per meal, in combination with resistance training. Compliance, however, can be difficult. Methods of inhibiting or reversing age-related sarcopenia by administering compositions comprising egg yolk powder are disclosed in U.S. patent 10,925,904 and 11,318,171. Alternative methods and compositions are needed to reduce and/or eliminate the side effects of sarcopenia and sarcopenia associated with rapid weight loss. Disclosure of Invention One aspect of the invention relates to a method for reducing muscle loss and/or inhibiting muscle loss associated with weight loss in a human by administering a composition comprising a yolk-derived product. In one non-limiting embodiment, the sarcopenia and/or sarcopenia is caused by a reduced calorie diet and/or weight-loss medication. In one non-limiting embodiment, the sarcopenia and/or sarcopenia is caused by a low calorie diet. In one non-limiting embodiment, the sarcopenia and/or sarcopenia results from administration of a weight-loss drug. In one non-limiting embodiment, the weight-reducing drug comprises semaglutin or telipopeptide. In one non-limiting embodiment, the composition comprising the egg yolk derived product is administered once, twice or three times per day. In one non-limiting embodiment, the composition comprising the egg yolk derived product comprises about 2 grams of protein per dose. In one non-limiting embodiment, the composition comprises a fertilized egg yolk derived product. In one non-limiting embodiment, the fertilized egg yolk derived product is FORTETROPIN. Detailed Description Many people taking glucagon-like peptide-1 (GLP-1) drugs such as Ozempic or Wegovy (semaglutin) and Mounjaro (telipopeptide) experience rapid weight loss. According to one clinical trial of Ozempic, 86.4% of the participants lost 5% or more weight and 69.1% of the participants lost 10% or more weight after 68 weeks of administration of the drug. While weight loss may provide health benefits, rapid weight loss may also lead to decreased muscle mass, decreased bone density, and decreased resting metabolic rate, leading to sarcopenia. As demonstrated herein, in dogs on a low calorie diet, administration of a composition comprising egg yolk derived products reduced muscle loss associated with rapid weight loss. It is expected that administration of a composition comprising a yolk derived product will have similar utility in reducing muscle loss and/or inhibiting sarcopenia in humans who are also taking weight-loss drugs. It is expected that administration of a composition comprising a yolk derived product will be particularly useful in reducing muscle loss and/or inhibiting muscle loss in humans taking weight-loss drugs comprising semaglutin or telipopeptide. Accordingly, the present invention provides methods and compositions for reducing muscle loss and/or inhibiting muscle loss due to weight loss in a mammal by administering a composition comprising a yolk-derived pro